News and Comments

Cempra Stock has Been Cremated. Will Today's Good News Resurrect It?

  Monday, November 07, 2016

The nature the Presidential Election this time is weighing on investors’ chests and minds and mood and decisions. The stocks are typically reflecting investors’ inability to reason or make rational selection. Many are waiting for the election results to see whether they sell their portfolios or add to them. Negativity is the outcome fuelled by pessimism and by the simultaneous surfacing of articles and biographies of high ranking officials – all point to that political games are dominating every aspect of our lives, including the directions of our stocks’ moves.   More...

Regeneron and Sanofi Rheumatoid Arthritis Drug is Still Extremely Promising

  Monday, October 31, 2016

Regeneron (REGN) and Sanofi informed that the FDA has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for sarilumab. The drug  is an investigational interleukin-6 receptor (IL-6R) antibody for adult patients with moderately to severely active rheumatoid arthritis (RA). More...

Why We Are Ignoring the Temporary Selling of NKTR. See Also: Agenus Adjuvant in GSK Successful Shingles Vaccine

  Wednesday, October 19, 2016

There is nothing wrong with Nektar Therapeutics (NKTR). The stock is temporarily underperforming as traders are practicing their conviction that they must sell when a firm finances through dilution. The traders practice this law of thumb regardless of whether the financing aims at bringing wealth or invites for a catastrophe. We believe Nektar is walking the road towards creating wealth and growth through continued development of breakthrough products.    More...

Senator Sanders and Ariad

  Monday, October 17, 2016

Shares of Ariad Pharmaceuticals declined following Senator Bernie Sanders’ criticism of the high price of the firm’s drug Iclusig (ponatinib) on Twitter. More...

A Promising Strategic Agreement Between A Large and A Small Biotech Firms.

  Thursday, October 13, 2016

When plenty of news comes out of the biotech sector, we are left with no option but prioritizing. Connecting the dots also might serve some purpose, including smelling take-over possibilities that make sense or contribute to improvements of the treatments and of firms’ finances. Prioritizing comprises selecting as much as possible the most concrete subjects that are safe to explore.  More...

Alnylam: Some Acted Without Listening and Some Listened But Did Not Believe

  Thursday, October 06, 2016

Following recent reports of new onset or worsening peripheral neuropathy in patients with ATTR amyloidosis with cardiomyopathy (hATTR-CM) treated with Alnylam’s (ALNY) RNAi –based drug revusiran, The firm requested that the Data Monitoring Committee (DMC) review the reports and the Clinical trial data on an unblinded basis. After reviewing the reports, the DMC advised suspending the dosing of revusiran.   More...

Why Aerie Pharmaceuticals' Stock Rallied Today. What About Now?

  Thursday, September 15, 2016

 More...

Another CRISPR Gene Editing Company Decided to Go Public. What's Investors' Decision?

  Tuesday, September 13, 2016

Another gene editing firm, CRISPR Therapeutics decided to become publicly traded. On Friday, the private firm filed with the SEC planning for a $90 million initial public offering (IPO).    More...

Nektar Therapeutics: Crossing the Barriers and Sailing into the Future

  Tuesday, September 06, 2016

Filled with high hopes and great enthusiasm, we are following up on Nektar’s (NKTR) immunotherapy product NKTR-214, which is in trials by Mayo Clinic and MD Anderson cancer center. The product is a CD122-biased agonist designed to stimulate the patient's own immune system to kill tumor cells. The technology behind the molecule “targeted polymer conjugate technology” has been validated time and time again in clinical trials and in approved drugs marketed by Nektar partners mainly large pharmaceutical firms.  NKTR-214 uses Nektar's this technology to enable preferential activation of immunostimulatory IL-2 receptors. It is a novel mechanism of action in immunotherapy, which is what is attracting us to the drug, knowing in fact that existing IL-2 therapy activates both immunosuppressive as well as immune-stimulatory receptors, which has limited its utility in clinical settings before the surfacing of NKTR-214. More...

A New Option for Osteoporosis Treatment That Would Prevent Bone Fractures

  Tuesday, August 23, 2016

JAMA Publishes Positive Phase 3 Data for Abaloparatide in Postmenopausal Women with Osteoporosis More...


Recent Postings


Archive


Tags

SUNESIS PHARMACEUTICALS (SNSS) SERES THERAPEUTICS (MCRB) Anacor (ANAC) ARGOS (ARGS) REGULUS (RGLS) HALOZYME (HALO) Endometrial Cancer Sequenom (SQNM) NANTKWEST (NK) VANDA (VNDA) Galena (GALE) Sanofi (SNA) Tysabri Zerenex KERYX (KERX) Alnylam (ALNY) TOKAI (TKAOI) Biocryst (BCRX) INNOVIVA (INVA) Rapamune Bristol-Myers Squibb (BMY) Velcade (bortezomib) Sanofi-Aventis (SAN) CEMPRA (CEMP) NOVOCURE (NVCR) Micromet (MITI) CompuGen (CGEN) Exelixis (EXEL) SYNTA (SNTA) Ziofpharm (ZIOP) Seattle Genetics (SGEN) ACADIA (ACAD) Aimmune Therapeutics (AIMT) Ionis (IONS) ZALTRAP™ PTC Therapeutics (PTCT) Human Longevity (HLI) Theravance (THRX) Intercept (ICPT) Global Cell Therapeutics (GBT) AERIE PHARMACEUTICALS Illumina (ILMN) Abbott Laboratories (ABT) Pluristem (PSTI) BIOMARIN (BMRN) Dendreon (DNDN) Prolor Biotech (PBTH) ADVENTRIX (ANX) Trastuzumab-DM1 Sarepta (SRPT) Benlysta (belimumab) Mirati Therapeutics (MRTX) Telaprevir Sanofi (SNY) Anadys (ANDS) Intrexon (XON) Onyx (ONXX) Spike Therapeutics (ONCE) C4 Therapeutics Elan (ELN) Idenix (IDIX) Jazz Pharmaceuticals (JAZZ) Theravance Bio Pharma (TBPH) Regeneron (REGN) Valeant Pharmaceuticals International (VRX) Sangamo (SGMO) ABBVIE (ABBV) MODERNA Intermune (ITMN) AGOS (ARGS) Auspex (ASPX) Ridaforolimus NEKTAR (NKTR)) Herceptin Human Genome Sciences (HGSI) Advaxis (ADXS) Amgen (AMGN) OSI (OSIP) Revlimid (lenolidamide) JUNO (JUNO) Vertex (VRTX) AstraZeneca (AZN) Editas (EDIT) Roche (RHHBY) galapagos (GLPG) Agenus (AGEN Biogen Idec (BIIB) Roche (ROCHE) Bellicum (BLCM) Vitae Pharmaceuticals (VTAE) Inovio (INO) Alder Biopharmaceuticals (ALDR) Genentech Merck (MRK) Incyte (INCY) RenenxBio (RGNX) Cytokinetics (CYTK) Array Pharmaceuticals (ARRY) Adaptimmune (ADAP) Multiple Myeloma ISIS (ISIS) CRISPR Therapeutics (CRSP) Gilead (GILD) GlaxoSmithKline (GSK) IDERA (IDRA) Prosensa (RNA) KITE (KITE) Ariad (ARIA) GUARDIAN HEALTH Ocular Therapeutix (OCUL) Dynavax (DVAX) Xoma (XOMA) ImmunoGen (IMGN) Agenus (AGEN) ARCA (ABIO)